These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 30995968)
1. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs. E Williams B; Nelons D; Seaman A; Witkowska M; Ronan W; Wheelock H; Zaman A; Garcia J Int J Drug Policy; 2019 Oct; 72():138-145. PubMed ID: 30995968 [TBL] [Abstract][Full Text] [Related]
2. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments. Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984 [TBL] [Abstract][Full Text] [Related]
3. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376 [TBL] [Abstract][Full Text] [Related]
4. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Aas CF; Vold JH; Skurtveit S; Odsbu I; Chalabianloo F; Lim AG; Johansson KA; Fadnes LT Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):44. PubMed ID: 32605625 [TBL] [Abstract][Full Text] [Related]
5. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528 [TBL] [Abstract][Full Text] [Related]
6. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093 [TBL] [Abstract][Full Text] [Related]
7. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA; J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642 [TBL] [Abstract][Full Text] [Related]
8. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system. Butler K; Larney S; Day CA; Burns L Drug Alcohol Rev; 2019 Mar; 38(3):264-269. PubMed ID: 30548702 [TBL] [Abstract][Full Text] [Related]
9. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey. Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139 [TBL] [Abstract][Full Text] [Related]
10. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB; Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989 [TBL] [Abstract][Full Text] [Related]
11. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808 [TBL] [Abstract][Full Text] [Related]
12. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050 [TBL] [Abstract][Full Text] [Related]
13. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387 [TBL] [Abstract][Full Text] [Related]
14. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494 [TBL] [Abstract][Full Text] [Related]
15. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene. Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571 [TBL] [Abstract][Full Text] [Related]
16. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs. Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968 [TBL] [Abstract][Full Text] [Related]
17. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194 [TBL] [Abstract][Full Text] [Related]
18. Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago. Echevarria D; Gutfraind A; Boodram B; Major M; Del Valle S; Cotler SJ; Dahari H PLoS One; 2015; 10(8):e0135901. PubMed ID: 26295805 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh. Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689 [TBL] [Abstract][Full Text] [Related]
20. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. Bruggmann P; Grebely J Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]